K
Keiichi Kobayashi
Researcher at Kyorin University
Publications - 34
Citations - 709
Keiichi Kobayashi is an academic researcher from Kyorin University. The author has contributed to research in topics: Glioma & Temozolomide. The author has an hindex of 10, co-authored 29 publications receiving 501 citations.
Papers
More filters
Journal ArticleDOI
A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas
Hideyuki Arita,Hideyuki Arita,Kai Yamasaki,Yuko Matsushita,Taishi Nakamura,Taishi Nakamura,Asanao Shimokawa,Hirokazu Takami,Hirokazu Takami,Shota Tanaka,Akitake Mukasa,Mitsuaki Shirahata,Saki Shimizu,Kaori Suzuki,Kuniaki Saito,Keiichi Kobayashi,Fumi Higuchi,Takeo Uzuka,Ryohei Otani,Kaoru Tamura,Kazutaka Sumita,Makoto Ohno,Yasuji Miyakita,Naoki Kagawa,Naoya Hashimoto,Ryusuke Hatae,Koji Yoshimoto,Naoki Shinojima,Hideo Nakamura,Yonehiro Kanemura,Yoshiko Okita,Manabu Kinoshita,Kenichi Ishibashi,Tomoko Shofuda,Yoshinori Kodama,Kanji Mori,Yusuke Tomogane,Junya Fukai,Koji Fujita,Yuzo Terakawa,Naohiro Tsuyuguchi,Shusuke Moriuchi,Masahiro Nonaka,Hiroyoshi Suzuki,Makoto Shibuya,Taketoshi Maehara,Nobuhito Saito,Motoo Nagane,Nobutaka Kawahara,Keisuke Ueki,Toshiki Yoshimine,Etsuo Miyaoka,Ryo Nishikawa,Takashi Komori,Yoshitaka Narita,Koichi Ichimura +55 more
TL;DR: The findings suggest that a combination of IDH, TERT, and MGMT refines the classification of grade II-IV diffuse gliomas, and patients with TERT mutant-MGMT unmethylated GBM have the poorest prognosis.
Journal ArticleDOI
Enhanced tumor growth elicited by L-type amino acid transporter 1 in human malignant glioma cells.
Keiichi Kobayashi,Akiko Ohnishi,Jutabha Promsuk,Saki Shimizu,Yoshikatsu Kanai,Yoshiaki Shiokawa,Motoo Nagane +6 more
TL;DR: LAT1, the major transporter of system L, is frequently expressed at higher levels in high-gradegliomas than in low-grade gliomas and brain tissues, and it may play an important role in enhancing the rates of tumor cell proliferation and growth in vivo.
Journal ArticleDOI
Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors
Kohei Fukuoka,Kohei Fukuoka,Yonehiro Kanemura,Tomoko Shofuda,Shintaro Fukushima,Satoshi Yamashita,Daichi Narushima,Mamoru Kato,Mai Honda-Kitahara,Hitoshi Ichikawa,Takashi Kohno,Atsushi Sasaki,Junko Hirato,Takanori Hirose,Takashi Komori,Kaishi Satomi,Akihiko Yoshida,Kai Yamasaki,Yoshiko Nakano,Ai Takada,Taishi Nakamura,Taishi Nakamura,Hirokazu Takami,Hirokazu Takami,Yuko Matsushita,Tomonari Suzuki,Hideo Nakamura,Keishi Makino,Yukihiko Sonoda,Yukihiko Sonoda,Ryuta Saito,Teiji Tominaga,Yasuhiro Matsusaka,Keiichi Kobayashi,Motoo Nagane,Takuya Furuta,Takuya Furuta,Mitsutoshi Nakada,Yoshitaka Narita,Yuichi Hirose,Shigeo Ohba,Akira Wada,Katsuyoshi Shimizu,Kazuhiko Kurozumi,Isao Date,Junya Fukai,Yousuke Miyairi,Naoki Kagawa,Atsufumi Kawamura,Makiko Yoshida,Namiko Nishida,Takafumi Wataya,Masayoshi Yamaoka,Naohiro Tsuyuguchi,Takehiro Uda,Mayu Takahashi,Yoshiteru Nakano,Takuya Akai,Takuya Akai,Shuichi Izumoto,Masahiro Nonaka,Kazuhisa Yoshifuji,Yoshinori Kodama,Masayuki Mano,Tatsuya Ozawa,Vijay Ramaswamy,Michael D. Taylor,Toshikazu Ushijima,Soichiro Shibui,Mami Yamasaki,Hajime Arai,Hiroaki Sakamoto,Ryo Nishikawa,Koichi Ichimura +73 more
TL;DR: RelA fusion-negative ST-EPN appear to be a heterogeneous group of tumors that do not fall into any of the existing molecular subgroups and are unlikely to form a single category.
Journal ArticleDOI
Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy.
Koichi Ichimura,Shintaro Fukushima,Yasushi Totoki,Yuko Matsushita,Ayaka Otsuka,Arata Tomiyama,Tohru Niwa,Hirokazu Takami,Taishi Nakamura,Taishi Nakamura,Tomonari Suzuki,Kohei Fukuoka,Kohei Fukuoka,Takaaki Yanagisawa,Takaaki Yanagisawa,Kazuhiko Mishima,Yoichi Nakazato,Fumie Hosoda,Yoshitaka Narita,Soichiro Shibui,Akihiko Yoshida,Akitake Mukasa,Nobuhito Saito,Toshihiro Kumabe,Toshihiro Kumabe,Masayuki Kanamori,Teiji Tominaga,Keiichi Kobayashi,Saki Shimizu,Motoo Nagane,Toshihiko Iuchi,Masahiro Mizoguchi,Koji Yoshimoto,Kaoru Tamura,Taketoshi Maehara,Kazuhiko Sugiyama,Mitsutoshi Nakada,Keiichi Sakai,Yonehiro Kanemura,Masahiro Nonaka,Akio Asai,Kiyotaka Yokogami,Hideo Takeshima,Nobutaka Kawahara,Tatsuya Takayama,Tatsuya Takayama,Masahiro Yao,Mamoru Kato,Hiromi Nakamura,Natsuko Hama,Ryuichi Sakai,Toshikazu Ushijima,Masao Matsutani,Tatsuhiro Shibata,Tatsuhiro Shibata,Ryo Nishikawa +55 more
TL;DR: The findings indicate that the dominant genetic drivers of GCTs regardless of the site of origin are activation of the MAPK and/or PI3K pathways by somatic point mutations.
Journal ArticleDOI
Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Protein Expression in Patients with Recurrent Glioblastoma Treated with Temozolomide
TL;DR: The standard 5-day TMZ regimen resulted in moderate antitumor activity with an acceptable safety profile in patients with nitrosourea-pretreated recurrent GBM, and protein expression of MGMT is an important prognostic factor for patients treated with TMZ even after recurrence.